ReviewJournal of ovarian research2026
Mechanisms of mitochondrial dysfunction in premature ovarian insufficiency.
Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Premature ovarian insufficiency (POI) is a clinical syndrome characterized by the decline of ovarian function in women under the age of 40, and its core pathological feature is the irreversible depletion of the ovarian reserve. Mitochondria serve as the central hub for energy metabolism and signal integration in ovarian cells, and their dysfunction drives POI progression through multiple cell death pathways and signaling cascades. This review systematically examines the multidimensional mechanisms by which mitochondrial damage leads to follicle depletion and proposes, for the first time, an integrated regulatory model termed "mitochondrial damage - follicle fate decision." The review further identifies contradictory evidence, model limitations, and gaps in clinical translation within current research. Regarding therapeutic strategies, we evaluate the current status, safety risks, and ethical barriers of mitochondrial nutrients, stem cell therapy, gene editing, and mitochondrial replacement therapy. Finally, we propose a future research framework centered on mitochondrial dynamics and quality control, emphasizing the need for multi-omics integration and personalized interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.